Skip to main content

Advertisement

SpringerLink
Log in

Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Histone deacetylase enzymes, confirmed to have important role in the pathogenesis of leukemia, are promising targets of epigenetic treatment. However, in acute myeloid leukemia, our knowledge on their expression levels is limited, and controversial data have been published about their potential oncogenic or tumorsuppressor properties in solid tumors. In our study, the expression levels of HDAC4 and SIRT6 were evaluated via Western blot analysis in 45 bone marrow samples (2 uninfiltrated and 43 concerned by different kinds of hematological malignancies), including 32 specimens obtained from patients with newly diagnosed AML. Significantly higher HDAC4 level was detected in case of FLT3-ITD mutation compared to the group of patients without carrying this mutation (p < 0.05). Compared to the non-infiltrated samples, the expression level of HDAC4 in AML M5 patients has been proved to be significantly higher (p < 0.05). Decreasing expression levels of both HDAC4 and SIRT6 were observed during the induction treatment of FAB M5 type AML. Strong correlation has been proved between the expression levels of HDAC4 and SIRT6 (r = 0.722 in full cohort and r = 0.794 in AML), that confirms the recently suggested cooperation between NAD+-independent and NAD+-dependent HDAC enzymes in leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

ALL:

Acute lymphoblastic leukemia

AML:

Acute myeloid leukemia

BCA:

Bicinchoninic acid assay

BSA:

Bovine serum albumin

CBP:

CREB-binding protein

CLL:

Chronic lymphocytic leukemia

FAB:

French-American-British Classification

FDA:

Food and Drug Administration

FLT3:

Fms-like tyrosine kinase 3

GCN5:

General control of amino acid synthesis 5

EDTA:

Ethylene-diamine-teraacetic acid

ETO:

Eight twenty one

HAT:

Histone acetyltransferase

HDAC:

Histone deacetylase

HCL:

Hairy cell leukemia

HL:

Hodgkin lymphoma

hMOF:

Human orthologue of the Drosophila melanogaster males absent on the first gene

HMT:

Histone methyltransferase

ITD:

Internal tandem duplication

JAK:

Janus kinase

MDS:

Myelodysplastic syndrome

MLL:

Mixed lineage leukemia

MPAL:

Mixed-phenotype acute leukemia

NCOR:

Nuclear receptor co-repressor

NPM1:

Nucleophosmin 1

NuRD:

Nucleosome remodeling deacetylase

PBX:

Pre-B-cell leukemia homeobox

PCBP2:

Poly(C)-binding protein 2

PRL3:

Phosphatase of regenerating liver cell 3

qPCR:

Quantitative polymerase chain reaction

RT:

Reverse transcription

SAHA:

Suberoylannilide hydroxamic acid

SDS:

Sodium dodecyl sulfate

SIRT:

Sirtuin

SMRT:

Silencing mediator of retinoid and thyroid hormone receptor

STAT:

Signal transducers and activators of transcription

TKD:

Tyrosine kinase domain

References

  1. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Linggi BE, Brandt SJ, Sun ZW, Hiebert SW (2005) Translating the histone code into leukemia. J Cell Biochem 96(5):938–950

    Article  CAS  PubMed  Google Scholar 

  3. Delcuve GP, Khan DH, Davie JR (2012) Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 4(1):5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370(Pt3):737–749

    Article  PubMed  PubMed Central  Google Scholar 

  5. Marks PA (2010) Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799(10–12):717–725

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yang XJ, Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9(3):206–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19(5):286–293

    Article  CAS  PubMed  Google Scholar 

  8. Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6(6):579–589

    Article  CAS  PubMed  Google Scholar 

  9. Bosch-Presegue L, Vaquero A (2011) The dual role of sirtuins in cancer. Genes Cancer 2(6):648–662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Saunders LR, Verdin E (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26(37):5489–5504

    Article  CAS  PubMed  Google Scholar 

  11. Liu H, Hu Q, D'Ercole AJ, Ye P (2009) Histone deacetylase regulates 11. Oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells. Glia 57(1):1–12

    Article  PubMed  PubMed Central  Google Scholar 

  12. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M et al (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10(1):92–100

    Article  CAS  PubMed  Google Scholar 

  13. Smith KT, Workman JL (2009) Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 41(1):21–25

    Article  CAS  PubMed  Google Scholar 

  14. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29(3):255–265

    Article  CAS  PubMed  Google Scholar 

  15. Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90(1):85–94

    Article  CAS  PubMed  Google Scholar 

  16. Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: what are the cancer relevant targets? Cancer Lett 277(1):8–21

    Article  CAS  PubMed  Google Scholar 

  17. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S et al (2007) Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ 14(8):1443–1456

    Article  CAS  PubMed  Google Scholar 

  18. Holmlund T, Lindberg MJ, Grander D, Wallberg AE (2013) GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia 27(3):578–585

    Article  CAS  PubMed  Google Scholar 

  19. Di Croce L (2005) Chromatin modifying activity of leukemia associated fusion proteins. Hum Mol Genet 14(Review Issue 1):R77–R84

    Article  CAS  PubMed  Google Scholar 

  20. Hackanson B, Rimmele L, Benkißer M, Abdelkarim M, Fliegauf M, Jung M et al (2012) HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res 36(8):1055–1062

    Article  CAS  PubMed  Google Scholar 

  21. Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC, Hentze H et al (2012) The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib(SB1518) in preclinical models of AML. Blood Cancer J 2(5):e69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O et al (2013) HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia 27(6):1358–1368

    Article  CAS  PubMed  Google Scholar 

  23. Tran HT, Kim HN, Lee IK, Nguyen-Pham TN, Ahn JS, Kim YK et al (2013) Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin a. J Korean Med Sci 28(2):237–246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L et al (2011) Synergistic interactions between HDAC and Sirtuin inhibitors in human leukemia cells. PLoS ONE 6(7):e22739

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L et al (2012) HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 7(12):1403–1412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yu SL, Lee DC, Son JW, Park CG, Lee HY, Kang J (2013) Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells. Oncol Rep 30(3):1293–1300

    CAS  PubMed  Google Scholar 

  27. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D et al (2008) HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19(10):4062–4075

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhu L, Yang J, Zhao L, Yu X, Wang L, Wang F et al (2015) Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma. Int J Oncol 46(6):2535–2545

    CAS  PubMed  Google Scholar 

  29. Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P et al (2013) Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol 31(8):1770–1779

    Article  CAS  PubMed  Google Scholar 

  30. Gruhn B, Naumann T, Gruner D, Walther M, Wittig S, Becker S et al (2013) The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leuk Res 37(10):1200–1207

    Article  CAS  PubMed  Google Scholar 

  31. Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L et al (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6):1185–1199

    Article  PubMed  PubMed Central  Google Scholar 

  32. Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E et al (2013) SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 34(7):1476–1486

    Article  CAS  PubMed  Google Scholar 

  33. Chen X, Hao B, Liu Y, Dai D, Han G, Li Y et al (2014) The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma. Biochem Biophys Res Commun 446(1):364–369

    Article  CAS  PubMed  Google Scholar 

  34. Fukuda T, Wada-Hiraike O, Oda K, Tanikawa M, Makii C, Inaba K et al (2015) Putative tumor suppression function of SIRT6 in endometrial cancer. FEBS Lett 589(17):2274–2281

    Article  CAS  PubMed  Google Scholar 

  35. Zhang ZG, Qin CY (2014) Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal-regulated kinase signaling pathway. Mol Med Rep 9(3):882–888

    CAS  PubMed  Google Scholar 

  36. Zhang J, Yin XJ, Xu CJ, Ning YX, Chen M, Zhang H et al (2015) The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of notch 3 expression. Eur Rev Med Pharmacol Sci 19(5):818–824

    CAS  PubMed  Google Scholar 

  37. Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C et al (2011) Histone deacetylase in chronic lymphocytic leukemia. Oncology 81(5–6):325–329

    Article  CAS  PubMed  Google Scholar 

  38. Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S et al (2011) PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS ONE 6(5):e19798

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors are grateful for Dóra Dedinszki, Zoltán Kónya (Department of Medical Chemistry, University of Debrecen) and Zsuzsanna Nagy (Department of Physiology, University of Debrecen) for the useful technical advices.

Our work was partially financed by Astellas Pharma Ltd.

Author information

Authors and Affiliations

  1. Department of Physiology, University of Debrecen, Nagyerdei krt. 98, PO box 22, Debrecen, H-4012, Hungary

    Zsuzsanna Gaál & László Csernoch

  2. Institute of Pediatrics, University of Debrecen, Nagyerdei krt. 98, PO box 22, Debrecen, H-4012, Hungary

    Éva Oláh

  3. Institute of Internal Medicine, University of Debrecen, Nagyerdei krt 98, PO box 22, Debrecen, H-4012, Hungary

    László Rejtő

  4. Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, PO box 22, Debrecen, H-4012, Hungary

    Ferenc Erdődi

Authors
  1. Zsuzsanna Gaál
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Éva Oláh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. László Rejtő
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ferenc Erdődi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. László Csernoch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to László Rejtő.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Author Contributions

Gaál Zs.: experimental procedures, design research, data analysis, writing the manuscript.

Oláh É.: design research, supervision of experimental procedures, correction of the manuscript.

Rejtő L.: collection of bone marrow specimens.

Erdődi F.: providing laboratory background (Department of Medical Chemistry), design research, supervision of experimental procedures, correction of the manuscript.

Csernoch L.: design research, supervision of experimental procedures, correction of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaál, Z., Oláh, É., Rejtő, L. et al. Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults. Pathol. Oncol. Res. 23, 493–504 (2017). https://doi.org/10.1007/s12253-016-0139-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-016-0139-5

Keywords

Search

Navigation